Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Cancer Discovery|2024Cited by 30
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancyRobert L. Bowman, Ross L. Levine, Sara E. Meyer et al.|Cancer Cell|2024Cited by 12
Supplementary Table S4 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Unknown|2024Cited by 0
Supplementary Figure S3 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Unknown|2024Cited by 0
Supplementary Table S2 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Unknown|2024Cited by 0